Literature DB >> 6696240

Malignant hyperthermia after oral and intravenous pretreatment with dantrolene in a patient susceptible to malignant hyperthermia.

G Ruhland, A J Hinkle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6696240     DOI： 10.1097/00000542-198402000-00017

Source DB:  PubMed          Journal:  Anesthesiology        ISSN： 0003-3022            Impact factor:   7.892


× No keyword cloud information.
  6 in total

1.  Propofol in a patient at risk for malignant hyperthermia: report of a case.

Authors:  Yuka Shimonagano; Yoshitami Kadota; Koichi Kawasaki; Takashi Gushiken; Nozomu Yoshimura
Journal:  J Anesth       Date:  1998-06       Impact factor: 2.078

2.  Availability of dantrolene in Canadian hospitals.

Authors:  R Paasuke; A K Brownell
Journal:  Can Anaesth Soc J       Date:  1985-09

Review 3.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

4.  Malignant hyperthermia.

Authors:  L Taiclet
Journal:  Anesth Prog       Date:  1985 Jul-Aug

5.  Malignant hyperthermia: a possible new variant.

Authors:  D S Lee; J P Adams; J E Zimmerman
Journal:  Can Anaesth Soc J       Date:  1985-05

6.  Malignant hyperthermia in an office surgery suite: a case report.

Authors:  I M Turpin; J Manino
Journal:  Aesthetic Plast Surg       Date:  1989       Impact factor: 2.326
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.